Cardiol therapeutics reports results of 2024 annual general and special meeting of shareholders

Toronto, ontario--(newsfile corp. - june 27, 2024) - cardiol therapeutics inc. (nasdaq: crdl) (tsx: crdl) ("cardiol" or the "company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "meeting") held virtually via live audio webcast, on june 26, 2024. shareholders voted in favour of all management resolutions proposed in the company's management information circular dated may 13, 2024.
GM Ratings Summary
GM Quant Ranking